Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with CRE infections who received ceftazidime/avibactam compared with comparative group (received different CRE specific antibiotics)

From: Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae

Characteristic Ceftazidime/Avibactam group n = 10 (%) Comparative group n = 28 (%) P value
Male 8 (80) 16 (57.1) 0.27
Age, median (IQR), y 59.5 (26–67) 61.5 (50–72) 0.71
CCI, median (IQR) 5.5 (2–8.5) 5 (4–7.75) 0.86
Baseline comorbidities
 Diabetes mellitus 4 (40) 15 (53.6) 0.71
 Hypertension 5 (50) 18 (64.3) 0.47
 CVD 4 (40) 9 (32.1) 0.71
 Renal disease 3 (30) 12 (42.8) 0.71
 Malignancy 5 (50) 7 (25) 0.24
 Transplant 5 (50) 5 (17.9) 0.09
 HIV 0 1 (3.6) > 0.99
Time from admission to first isolate of CRE culture (days), median (IQR), days 22.5 (4.75–50.75) 17 (5.25–29.25) 0.71
CRE Bacteremia 7 (70) 15 (53.6) 0.47
Type of infection
 CLABSI 1 (10) 4 (14.3) > 0.99
 HAP 5 (50) 14 (50) > 0.99
 cUTI 3 (30) 8 (28.6) > 0.99
 cIAI 3 (30) 5 (17.8) 0.41
 SSTI 2 (20) 3 (10.7) 0.59
Microbiology
Klebsiella pneumoniae 7 (70) 23 (82.1) 0.41
Escherichia coli 3 (30) 5 (17.9)  
Time from first CRE culture to starting CRE specific therapy, median (IQR), days 3.5 (1–8.75) 0 (0–1) 0.05
  1. IQR Interquartile range, CCI Charlson comorbidity index, CVD Cardiovascular disease, HIV Human immunodeficiency virus, CLABSI Central Line-associated blood stream infection, CRE Carbapenem-resistant Enterobacteriaceae, HAP Hospital-acquired pneumonia, cUTI Chronic urinary tract infection, cIAI complicated intra-abdominal infection, SSTI Soft tissue infection